Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: whether the FDA will approve the NDA for our TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; our ability to maintain or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and one-year contraceptive vaginal system licensed product and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the length, cost and uncertain results of our clinical trials; potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates or adversely affect the commercialization of our current or future approved products; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

TX-001HR, TX-005HR, and TX-006HR are investigational drugs and are not approved by the FDA. This non-promotional presentation is intended for investor audiences only.
TherapeuticsMD, A Premier Women’s Health Company

Annovera™

CONTRACEPTION

vitaMedMD®

PRENATAL CARE

Annovera™

CONTRACEPTION/
FAMILY PLANNING -
PERIMENOPAUSE

TX-Q01HR*

VASOMOTOR
SYMPTOMS

Imvexxy™

DYSPAREUNIA
(Vulvar &
Vaginal Atrophy)

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

*Investigational product, pending FDA approval
Seasoned Management Team with a Proven Track Record of Commercial Execution

Tommy Thompson
Chairman of the Board
- Former US Secretary of Health and Human Services (2001-2005)
- Holds multiple board memberships, including Centene and United Therapeutics
- 40-year public health career

Angus Russell
Board Member
- Former Chief Executive Officer and Chief Financial Officer of Boehringer Ingelheim (US)
- Former Vice President of Corporate Finance at AstraZeneca
- Holds multiple board memberships, including Chairman of Revance Therapeutics

J. Martin Carroll
Board Member
- Former President and Chief Executive Officer of Boehringer Ingelheim (US)
- Former EVP of Customer Marketing and Sales of US Human Health at Merck
- Holds multiple board memberships, including Catalent

Jane Barlow
Board Member
- 25 years of clinical and strategic healthcare experience
- Former Chief Medical Officer of CVS Health’s Medicare and Government Services
- Former Vice President of Clinical Innovation at MEDCO Health Solutions

Robert Finizio
CEO, Co-Founder, and Director
- Co-founded vitaMedMD in 2008
- Co-founded CareFusion (Sold to Cardinal Health in 2006)
- 22 years of experience in early stage healthcare company development

Brian Bernick, MD
Co-Founder and Director
- Co-founded vitaMedMD in 2008
- 25 years of experience in healthcare/women’s health
- Past OB/GYN Department Chair - Boca Raton Regional Hospital
- Past ACOG Committee Member
- OB/GYN – trained University of Pennsylvania

Tom Diefendorf
President
- Co-founder CareFusion
- Held executive sales and operation management positions at McKesson, Cardinal, and Omnicell
- 20+ years of operations experience

Dan Cartwright
Chief Financial Officer
- Former CFO of American Wireless, Telegeography, and WEB Corp
- Participated in American Wireless/Arush Entertainment merger
- Former KPMG and PricewaterhouseCoopers accountant

Sebastian Mirkin, M.D.
Chief Medical Officer
- Former Clinical Lead of Women’s Health at Pfizer
- 15+ years of experience developing women’s health products
- Reproductive endocrinologist & infertility specialist

Dawn Hakuff
Chief Commercial Officer
- 20+ years of commercial and marketing experience
- SVP of the Pfizer Consumer Healthcare Wellness Organization
- Commercial lead for sales and marketing of the Pfizer Women’s Health Division

Julia Amadio
Chief Product Officer
- 25+ years of women’s health pharmaceutical experience
- Product development leader for J&J, Wyeth, Aventis, and others
- Worked on development of Prempro®, Premphase®, and Estalis®

Christian Bloomgren
VP, Sales
- 16+ years of experience in the pharmaceuticals and biotech
- Created a national sales channel, led the Specialty Diagnostics business at ViaCell, Inc.
- Product launch and sales management roles at Eli Lilly & Company and KV Pharmaceutical

John Milligan
President
- Co-founded CareFusion
- Held executive sales and operation management positions at McKesson, Cardinal, and Omnicell
- 20+ years of operations experience

Jane Barlow
Board Member
- 25 years of women’s health pharmaceutical experience
- Product development leader for J&J, Wyeth, Aventis, and others
- Worked on development of Prempro®, Premphase®, and Estalis®

Board Member
- Co-founded CareFusion (Sold to Cardinal Health in 2006)
- 22 years of experience in early stage healthcare company development

Former President and Chief Executive Officer of Boehringer Ingelheim (US)
- Former EVP of Customer Marketing and Sales of US Human Health at Merck
- Holds multiple board memberships, including Catalent

Former CFO of American Wireless, Telegeography, and WEB Corp
- Participated in American Wireless/Arush Entertainment merger
- Former KPMG and PricewaterhouseCoopers accountant

Former Clinical Lead of Women’s Health at Pfizer
- 15+ years of experience developing women’s health products
- Reproductive endocrinologist & infertility specialist

20+ years of commercial and marketing experience
- SVP of the Pfizer Consumer Healthcare Wellness Organization
- Commercial lead for sales and marketing of the Pfizer Women’s Health Division

25+ years of women’s health pharmaceutical experience
- Product development leader for J&J, Wyeth, Aventis, and others
- Worked on development of Prempro®, Premphase®, and Estalis®

16+ years of experience in the pharmaceuticals and biotech
- Created a national sales channel, led the Specialty Diagnostics business at ViaCell, Inc.
- Product launch and sales management roles at Eli Lilly & Company and KV Pharmaceutical

Insiders own approximately ~20% of total outstanding shares
Responsible and Financially Disciplined Approach to Delivering Results

- TXMD has a 10 year history of delivering strong results in a financially efficient manner

- We have two recent product approvals (Imvexxy and Annovera) and a PDUFA target action date for TX-001HR of October 28, 2018

- We remain well-financed, including our flexibility of having an additional $125M through our term loan with MidCap Financial
  - $75M on approval and first commercial sale of TX-001HR on or before May 31, 2019
  - Additional $50M on hitting Imvexxy and TX-001HR 12 month net revenue threshold on or before December 31, 2019

- The next phase of growth is expected to be through promotion and sales of Imvexxy, Annovera and TX-001HR, if approved
## Track Record of Execution

<table>
<thead>
<tr>
<th>Date</th>
<th>Milestone/ Catalyst</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/14/13</td>
<td>First Registered Equity Offering</td>
</tr>
<tr>
<td>8/5/13</td>
<td>Commenced Phase 3 Replenish Trial of TX-001HR</td>
</tr>
<tr>
<td>9/29/14</td>
<td>Commenced Phase 3 Rejoice Trial of TX-004HR (Imvexxy)</td>
</tr>
<tr>
<td>12/7/15</td>
<td>Positive Top-Line Results from Phase 3 Rejoice Trial of TX-004HR (Imvexxy)</td>
</tr>
<tr>
<td>7/7/16</td>
<td>Submission of New Drug Application for Imvexxy</td>
</tr>
<tr>
<td>12/5/16</td>
<td>Positive Top-Line Results from Phase 3 Replenish Trial of TX-001HR</td>
</tr>
<tr>
<td>12/28/17</td>
<td>Submission of New Drug Application for TX-001HR</td>
</tr>
<tr>
<td>5/29/18</td>
<td>Received FDA Approval of New Drug Application for Imvexxy</td>
</tr>
<tr>
<td>7/31/18</td>
<td>Acquired US Rights to Annovera from the Population Council</td>
</tr>
<tr>
<td>7/31/18</td>
<td>Entered into Strategic Partnership with Knight Therapeutics for Imvexxy and TX-001HR</td>
</tr>
<tr>
<td>8/6/18</td>
<td>Commenced US Commercial Launch of Imvexxy</td>
</tr>
<tr>
<td>8/10/18</td>
<td>Received FDA Approval of New Drug Application for Annovera</td>
</tr>
<tr>
<td>10/28/18</td>
<td>PDUFA Date for TX-001HR – Potential to have Three Approved Drugs in One Year</td>
</tr>
</tbody>
</table>

Total of 241 global patent applications with 22 issued foreign patents and 20 issued U.S. patents for Imvexxy and TX-001HR
# Women’s Health Assets With Large Total Addressable Market Opportunities

## Annovera™
- **Indication**: Females to prevent pregnancy
- **Condition Description**: Contraception
- **Active Ingredients**: Segesterone Acetate/Ethinyl Estradiol
- **Form**: Vaginal System
- **Key Value Proposition**: First and only patient-controlled, procedure-free, long-acting, reversible birth control product
- **Affected US Population**: 43 million women
- **US TAM Opportunity**: $5B
- **Status**: Approved Aug. 10, 2018 Commercial Launch: Est. 4Q19-1Q20

## TX-001HR
- **Indication**: Moderate to severe vasomotor symptoms (VMS) due to menopause*
- **Condition Description**: VMS due to Menopause
- **Active Ingredients**: Bio-Identical 17 β-Estradiol + Bio-Identical Progesterone
- **Form**: Oral softgel capsule
- **Key Value Proposition**: Potential first and only bio-identical FDA-approved combination product
- **Affected US Population**: 36 million women
- **US TAM Opportunity**: >$25B
- **Status**: PDUFA Target Action Date: Oct. 28, 2018

## Imvexxy™
- **Indication**: Moderate to severe dyspareunia, a symptom of VVA, due to menopause
- **Condition Description**: VVA due to Menopause
- **Active Ingredients**: Bio-Identical 17 β-Estradiol
- **Form**: Vaginal softgel insert
- **Key Value Proposition**: Easy to use, lowest approved dose, designed to support patient adherence
- **Affected US Population**: 32 million women
- **US TAM Opportunity**: >$20B
- **Status**: Approved May 29, 2018 Commercial Launch: August 2018

---

*Potential indication; pending FDA approval*

2) QuintilesIMS MIDAS, QuintilesIMS Analysis, Company filings. Long acting reversible contraceptive market includes: Neplanon/Implanon, Mirena family, Paragard and Liletta. Net sales as reported in company filings.
3) Derived from U.S. Census data on women in the age group who normally experience symptoms.
4) Based on pre-WHI annual scripts of FDA-approved HT products.
7) Based on market pricing of current FDA-approved HT products.
Approved for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

Vulvar and Vaginal Atrophy (VVA) Program
Imvexxy Key Timeline

- 10 mcg national launch started on August 6, 2018
- 4 mcg commercially available on September 13, 2018
- Bio-Ignite went live August 10, 2018 with 12 pharmacies ordering Imvexxy
Imvexxy Launch Update
through September 27, 2018

- Over 14,000 units (scripts) of Imvexxy have been dispensed by pharmacies and paid for by over 8,100 patients*
  - 11,160 - maintenance packs
  - 2,890 - starter packs

- 78% of patients are enrolled in commercial insurance with 11% currently being able to be adjudicated based on current insurance coverage for Imvexxy

- 44% of patients received their 2nd paid refill

- Average patient has an additional 10 authorized refills on the maintenance pack

- Over 3,700 prescribers have written a prescription for Imvexxy

*Based on utilization of our affordability programs. Cash pay or covered by insurance. 99% of patients paid an out of pocket copay between $15 to $35 to fill their prescription.
Update on Insurance Coverage

- ~36% unrestricted commercial coverage (no step edits and no PA) as of September 27, 2018
  - TXMD will start to see the financial benefit of coverage and incremental increase in net revenue approximately 90 days following gaining commercial coverage
  - Net revenue for Imvexxy is expected to peak at ~60% when insurance coverage is fully established

- Top 3 FDA-approved VVA products (Estrace, Premarin and Vagifem) top out at 65%+ unrestricted commercial coverage
  - Not including Medicare Part D which comprises 25% of script volume
Net Revenue Ramp for Commercially Insured Patients

- TXMD already working to achieve prescriber and patient adoption, prior to full commercial insurance coverage
- The 90 day lag in commercial payer reimbursement will have a short-term negative impact on net revenue due to TXMD affordability programs
- As the patient base becomes covered by commercial insurance, TXMD expects net revenue to be on average 60% of WAC
- Commercial insurance coverage for Imvexxy expected to be fully established by 4Q 2019
  - Product mix during this growth phase currently expected to be two starter packages for every three maintenance packages
    - Starter pack:
      - WAC $405
      - 60% net = $243 average net revenue per unit (script)*
    - Maintenance pack:
      - WAC $180
      - 60% net = $108 average net revenue per unit (script)*
    - Blended starter/maintenance expected
      - Avg. WAC $270**
      - 60% net = $162 net revenue per unit (script)*
- With fully established coverage, we expect Imvexxy to support our goal of reaching profitability

*Estimated net revenue for a script with commercial reimbursement, which accounts for wholesaler distribution cost, payer discounts and patient savings program.
**Based on product mix during growth phase, which is expected to be two starter packs to every three maintenance packs.
Relationship of Commercial Lives Covered Versus Imvexxy Covered Claims and Realized Net Revenue

Trendline in chart based on TXMD historical experience and other products

- % of Commercial Lives Covered
- % of Rxs Paid by Commercial Insurance
- Net Revenue as a % of WAC

* No net revenue generation today. TXMD will start to see the financial benefit of coverage and incremental increase in net revenue approximately 90 days following gaining commercial coverage.

**GTN in 1Q 2019 impacted by insurance plan resets

References:
1. MMIT
Achieving 60% net revenue assumes access to top 10 commercial payers by 4Q 2019
Recently achieved ~67% unrestricted commercial access with Express Scripts and ~93% with Anthem
We are in various stages of the negotiation process with the other top 10 commercial payers
Emphasis on payers with patients in our top VVA prescribing states of Florida, Texas and California

<table>
<thead>
<tr>
<th>Top 10 Commercial Payers</th>
<th>Percentage of Total Lives Covered*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Express Scripts</td>
<td>15.5%</td>
</tr>
<tr>
<td>CVS Caremark</td>
<td>14.6%</td>
</tr>
<tr>
<td>Prime</td>
<td>8.2%</td>
</tr>
<tr>
<td>Anthem</td>
<td>7.7%</td>
</tr>
<tr>
<td>United</td>
<td>7.7%</td>
</tr>
<tr>
<td>OptumRx</td>
<td>5.9%</td>
</tr>
<tr>
<td>Aetna, Inc.</td>
<td>5.1%</td>
</tr>
<tr>
<td>CIGNA Health Plans Inc.</td>
<td>4.1%</td>
</tr>
<tr>
<td>Kaiser Foundation Health Plans</td>
<td>4.0%</td>
</tr>
<tr>
<td>Blue Cross Blue Shield</td>
<td>2.9%</td>
</tr>
</tbody>
</table>
Payer Breakdown of FDA-Approved VVA Products

- As of September 27, 2018, Imvexxy achieved ~36% unrestricted commercial coverage (no step edits or PA)
  - Expect commercial coverage to peak at 60%+
- Earliest expected Medicare Part D coverage for Imvexxy would be January 1, 2019
- Historical trends show recent launch of Intrarosa getting to ~65% unrestricted commercial access 9 months after field launch

1 MMIT Data April 2018
2 MMIT
Vulvar and Vaginal Atrophy (VVA)

- A component of genitourinary syndrome of menopause (GSM)
- **Chronic** and **progressive** condition that results from decreased estrogen levels characterized by thinning of vaginal tissue
- Diagnosed in approximately **50%** of postmenopausal women
- Primary symptom = dyspareunia (painful intercourse)
- Secondary symptoms include: vaginal dryness, itching, irritation, bleeding with sexual activity, dysuria, urgency, frequency, recurrent UTIs, and incontinence
- Current treatments include: prescription hormone creams, tablets, and rings in addition to over-the-counter lubricants

---

**Healthy Vaginal Tissue**
- Thick
- Moist
- High estrogen level
- Low pH (<5)
- Increased superficial cells (>15%)
- Decreased parabasal cells (<5%)

**Atrophic Vaginal Tissue**
- Thin
- Dry
- Low estrogen level
- High pH (>5)
- Decreased superficial cells (<5%)
- Increased parabasal cells (>30%)

---

Current US VVA Market Overview

32M with VVA symptoms (1 out of 2 menopausal women) in the United States\(^1,2\)

50\% (16M) seek treatment for VVA\(^4\)
- 25\% (8M) OTC products
- 18\% (5.7M) past HT users
- 7\% (2.3M) current HT users

Only 7\% (2.3M) are current users of Rx hormone therapy\(^3\)

- Long-term safety concerns\(^5\)
- Efficacy\(^5\)
- Messiness\(^5\)
- Need for applicator\(^5\)

American College of Obstetricians and Gynecologists (ACOG)¹
“Low-dose and ultra-low systemic doses of estrogen may be associated with a better adverse effect profile than standard doses and may reduce vasomotor symptoms in some women.”

North American Menopause Society (NAMS)²
“The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate the woman’s personal risk factors and her quality-of-life priorities in this shared decision.”

FDA³
“...this guidance encourages sponsors to develop the lowest doses and exposures for both estrogens and progestins for indications sought, even though specific relationships between dose, exposure, and risk of adverse events may not be known.”

Imvexxy is “Redefining Relief”

Owning **clinical** attributes with the underpinning of a highly effective patient experience

### Key Clinical Attributes:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>New lowest approved dose</td>
</tr>
<tr>
<td>2</td>
<td>Strong efficacy and safety data</td>
</tr>
<tr>
<td>3</td>
<td>Improvement seen at week 12 (primary) and as early as 2 weeks (secondary)</td>
</tr>
<tr>
<td>4</td>
<td>PK data where systemic hormone levels remain within normal postmenopausal range</td>
</tr>
</tbody>
</table>

### Key Physical Attributes:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Ease of use and absence of applicator</td>
</tr>
<tr>
<td>6</td>
<td>Ability to be used any time of day</td>
</tr>
<tr>
<td>7</td>
<td>A mess-free way to administer</td>
</tr>
<tr>
<td>8</td>
<td>Dose packaging to optimize patient compliance and enhance provider and patient acceptance</td>
</tr>
</tbody>
</table>
Foundation Built for a Strong Launch

- 81% of total prescribers within current 150 TXMD territories\(^1\)
- 40% overlap with current prenatal vitamins business
- Sales force of 150
- Partnership with inVentiv, leading contract sales organization
- Operational and analytic systems

\(^1\) IQUVIA Data
### Current FDA-Approved VVA Products

**Local estrogen therapy currently represents over 95% market share in the VVA market**
- Current standard of care per medical society guidelines
- Current poor compliance within the class
- Imvexxy is the new lowest approved dose with potential for improved compliance

**30-day WAC Maintenance dose pricing $180 for IMVEXXY**
- Near parity w/ Vagifem ($170.16) & less than newest entrants Intrarosa ($198.75), Osphena ($203.80)

---

| Product                  | Estrace® Cream (estradiol vaginal cream, USP, 0.01%)
|--------------------------|------------------------------------------------------
|                          | Premarin Cream® (conjugated estrogens)                |
|                          | Estring® (estradiol vaginal Ring)                     |
|                          | Vagifem® (estradiol vaginal inserts)                  |
|                          | IMVEXXY (estradiol vaginal inserts§,§)                |
|                          | Intrarosa® (prasterone vaginal inserts)               |
|                          | Osphena® (ospemifene tablets)                        |

**FDA approval**
- 1984
- 1978
- 1996
- 1999
- 2018
- 2016
- 2013

**Active Ingredient**
- 100μg estradiol
- 625 μg conjugated equine estrogens
- 2,000 μg estradiol
- 10μg estradiol
- 4 μg or 10 μg estradiol
- 6,500 μg prasterone
- 60,000 μg ospemifene

**TRx MSB Dollars 2017§
- $504,804,770
- $463,264,428
- $105,169,311
- $446,044,670
- $3,597,519
- $66,904,883

**Method of administration**
- Vaginal Cream
- Vaginal Cream
- Vaginal Ring
- Tablet Vaginal Insert
- Softgel Vaginal Insert
- Vaginal Insert
- Oral Tablet

**WAC package price (2018)§
- $314.87 (42.5-g tube)
- $355.77 (30-g tube)
- $431.34 (1 ring)
- $170.16 (8 tablets)
- $180.00 (8 inserts)
- $185.50 (28 inserts)
- $198.75 (28 inserts)
- $203.80 (90 tablets)

**Calculated WAC 30-day supply (2018)§
- $104.96
- $118.59
- $143.78
- $170.16
- $180.00
- $198.75
- $203.80

---

**References:**
VVA Class Commercial Coverage:¹
Top 25 payers represent ~87% of Commercial lives with a majority of access unrestricted

<table>
<thead>
<tr>
<th>Vulvar and Vaginal Atrophy- 184,277,713 Commercial Lives</th>
<th>Commercial Lives</th>
<th>Estrace Cream</th>
<th>Intrarosa</th>
<th>Osphena</th>
<th>Premarin Cream</th>
<th>Vagifem</th>
<th>Yuvafem</th>
<th>Estring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlling Payer/PBM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Express Scripts PBM</td>
<td>28,507,971</td>
<td>14%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>CVS Caremark RX</td>
<td>27,256,869</td>
<td>15%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>Anthem, Inc.</td>
<td>14,385,833</td>
<td>8%</td>
<td>Covered</td>
<td>Covered (PA/ST)</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>UnitedHealth Group, Inc.</td>
<td>13,571,816</td>
<td>7%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>OptumRx</td>
<td>11,762,164</td>
<td>6%</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Aetna, Inc.</td>
<td>7,903,792</td>
<td>4%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>Kaiser Foundation Health Plans, Inc.</td>
<td>7,453,024</td>
<td>4%</td>
<td>Preferred</td>
<td>Not Covered</td>
<td>Preferred</td>
<td>Not Covered</td>
<td>Not Covered</td>
<td>Preferred</td>
</tr>
<tr>
<td>CIGNA Health Plans, Inc.</td>
<td>7,408,428</td>
<td>4%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>Department of Defense - TRICARE</td>
<td>7,090,804</td>
<td>4%</td>
<td>Preferred</td>
<td>Preferred (PA/ST)</td>
<td>preferred</td>
<td>Preferred</td>
<td>Preferred</td>
<td>Preferred</td>
</tr>
<tr>
<td>Blue Cross Blue Shield Association Corporation</td>
<td>5,410,238</td>
<td>3%</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Health Care Service Corporation</td>
<td>5,290,357</td>
<td>3%</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Department of Veterans Affairs (VHA)</td>
<td>4,777,557</td>
<td>3%</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
<td>Preferred</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
</tr>
<tr>
<td>Envision Pharmaceutical Services</td>
<td>3,125,237</td>
<td>2%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Generic (Preferred)</td>
<td>Covered</td>
</tr>
<tr>
<td>Indian Health Service (IHS)</td>
<td>2,186,820</td>
<td>1%</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
<td>Preferred</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
</tr>
<tr>
<td>Blue Shield of California</td>
<td>1,840,474</td>
<td>1%</td>
<td>Covered</td>
<td>Covered (PA/ST)</td>
<td>Covered (PA/ST)</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
</tr>
<tr>
<td>CareFirst, Inc.</td>
<td>1,517,895</td>
<td>1%</td>
<td>Covered</td>
<td>Covered</td>
<td>Prefered</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
</tr>
<tr>
<td>EmblemHealth, Inc.</td>
<td>1,477,204</td>
<td>1%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of Michigan</td>
<td>1,399,562</td>
<td>1%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
</tr>
<tr>
<td>Humana, Inc.</td>
<td>1,212,751</td>
<td>1%</td>
<td>Covered</td>
<td>Not Covered</td>
<td>Not Covered</td>
<td>Not Covered</td>
<td>Not Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Blue Cross and Blue Shield of Florida, Inc.</td>
<td>1,207,374</td>
<td>1%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of Minnesota</td>
<td>1,173,171</td>
<td>1%</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>State of New York</td>
<td>1,092,511</td>
<td>1%</td>
<td>Not Covered</td>
<td>Preferred</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of North Carolina</td>
<td>1,061,152</td>
<td>1%</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Covered (PA/ST)</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Centene Corporation</td>
<td>1,012,171</td>
<td>1%</td>
<td>Covered (PA/ST)</td>
<td>Not Covered</td>
<td>Preferred</td>
<td>Covered (PA/ST)</td>
<td>Covered</td>
<td>Covered</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of Alabama</td>
<td>991,169</td>
<td>1%</td>
<td>Preferred</td>
<td>Covered</td>
<td>Covered</td>
<td>Preferred</td>
<td>Not Covered</td>
<td>Covered</td>
</tr>
</tbody>
</table>

References:
1. MMIT May 2018
Favorable Payer Dynamics: No Substitution Across Branded Products

Case Study: Vagifem® Generics Launch

- Yuvarfem launch in October 2016

<table>
<thead>
<tr>
<th></th>
<th>VVA TRx Market Share (%) Oct 2015-Sept 2016</th>
<th>VVA TRx Market Share (%) Oct 2016-April 2018</th>
<th>Gains (Losses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vagifem</td>
<td>29.7%</td>
<td>5.4%</td>
<td>-24.3%</td>
</tr>
<tr>
<td>Generic Estradiol Tablets (including Yuvarfem and others)</td>
<td>-</td>
<td>24.4%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Total</td>
<td>29.7%</td>
<td>29.8%</td>
<td>0.1%</td>
</tr>
</tbody>
</table>

- Yuvarfem continues to take market share from only Vagifem
- No substitution or cannibalization of other branded products
Prior Authorization Example in the VVA Class

- The majority of commercial payers do not require PA/ST for branded VVA treatments today¹
- However, select payers require written PA and step-through one or two preferred products in select cases
  - Unlikely for Imvexxy to step-edit through a higher dose vaginal estrogen product
- Low dose vaginal estrogen remains frontline therapy

Example 1: PA Criteria for Osphena at Anthem²

8. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY
NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request.

- Yes  No  Patient is female
- Yes  No  Patient has a diagnosis of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy (VVA) associated with menopause
- Yes  No  Patient has had a trial of, or insufficient response to one preferred vaginal estrogen product (that is, Premarin vaginal cream, Vagifem, or Femring)

References:
1. MMIT, May 2018
Recent VVA TRx Launch Trajectories Represent Reasonable Comparators for Imvexxy Launch in Year 1

Rate Limited Factors in Year 1 that Impact Launch:

- Limited number of new women going onto therapy each year
- Number of women that switch to a new product year 1
- The impact of the above factors is reduced in years 2 and beyond

References:
1. PHAST Symphony
TXMD’s Patient Engagement Programs for Adoption, Affordability & Adherence

- Developed over the past 6 years in an effort to improve the long term value of a patient through Education, Adherence and Co-Pay assistance
- TXMD utilizes standard pharmaceutical industry programs in a more coordinated and effective fashion – maximizing impact and results
- Program has achieved 78% utilization of the Co-Pay assistance program compared to an industry standard of 30%
- Created and piloted around the prenatal vitamin product line to enhance the launches of Imvexxy and TX-001HR (if approved)
Results of TXMD Prenatal Vitamin Adoption & Adherence Programs

**Patient Adherence**
- Industry Avg: 2.5 of 9 months
- TXMD Avg: 7 of 9 months

**Prescriber Loyalty**
- Industry Avg: 30 prescriptions per physician per year
- TXMD Avg: 71 prescriptions per physician per year

**Data Insights**
- Industry Avg: 60 days
- TXMD Avg: Real time Data
### Compliance and Fills Per Year Drives Top-Line Revenue

#### Current VVA Market

**Vaginal Creams:**

**Average:**

**1.5 Fills Per Year**

<table>
<thead>
<tr>
<th>Product</th>
<th>TRx Dollars</th>
<th>Patient Count</th>
<th>Patient Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrace</td>
<td>$583,612,698</td>
<td>900,618</td>
<td>41%</td>
</tr>
<tr>
<td>Premarin</td>
<td>$533,386,029</td>
<td>696,125</td>
<td>32%</td>
</tr>
<tr>
<td>Vagifem/Generics</td>
<td>$525,321,410(^a)</td>
<td>448,745</td>
<td>20%</td>
</tr>
</tbody>
</table>

**Reasons Women Stop**

- Messiness\(^1\)
- Reusable Applicator\(^1\)
- Long-term Safety\(^1\)
- Dose Preparation by User Required\(^3\)

**Vaginal Tablets:**

**Average:**

**3.5 Fills Per Year**

<table>
<thead>
<tr>
<th>Product</th>
<th>TRx Dollars</th>
<th>Patient Count</th>
<th>Patient Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrace</td>
<td>$533,386,029</td>
<td>696,125</td>
<td>32%</td>
</tr>
<tr>
<td>Premarin</td>
<td>$583,612,698</td>
<td>900,618</td>
<td>41%</td>
</tr>
<tr>
<td>Vagifem</td>
<td>$525,321,410(^a)</td>
<td>448,745</td>
<td>20%</td>
</tr>
</tbody>
</table>

**Reasons Women Stop**

- Efficacy\(^1\)
- Applicator\(^1\)
- Long-term Safety\(^1\)
- Systemic Absorption\(^1\)

- Higher average fills per year enable Vagifem/Yuvafem to generate equal revenue as Premarin and Estrace with significantly less patients on therapy

---

2) Total Rx/Patient Count
4) Symphony Health Solutions PHAST Data powered by IDV; Annual 2017
5) IMS SDI’s Total Patient Tracker; Annual 2017
Patient Engagement Program

Healthcare Provider Writes a Prescription

TXMD Affordability and Education Program

Affordability Program
Maximum Out-of-Pocket $35

Retail Pharmacy Fills Prescription

Engagement Program to Increase
Compliance and Adherence
Incremental Fills Per Year Drive Upside to Net Revenues

Each incremental fill per year can add an estimated $75M to Imvexxy net revenues

Year 5 Assumptions

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total VVA Patients on HT</td>
<td>2,300,000</td>
</tr>
<tr>
<td>Imvexxy Market Share</td>
<td>25 - 30%</td>
</tr>
<tr>
<td>Imvexxy Patients</td>
<td>665,000</td>
</tr>
<tr>
<td>WAC of Loading Dose</td>
<td>$405.00</td>
</tr>
<tr>
<td>WAC of Maintenance Dose</td>
<td>$180.00</td>
</tr>
<tr>
<td>Sum of Total Discounts per Rx</td>
<td>35%</td>
</tr>
</tbody>
</table>

1 Assumes zero market growth and zero price increases
2 IQVIA Total Patient Tracker (2017 Data)
TX-001HR

Combination Estrogen + Progesterone (E+P) Program

TX-001HR Update
- Entered into label discussions with FDA on September 27, 2018
- PDUFA target action date remains October 28, 2018
- We do not anticipate providing updates with respect to label discussions prior to the PDUFA target action date

There can be no assurance that the FDA will approve the NDA for TX-001HR, or that such approval will occur by the PDUFA target action date, and the entrance into label discussions does not imply otherwise.
TX-001HR Product Development Rationale

- 2002 Women’s Health Initiative (WHI) study showed that the long-term use of certain synthetic hormones (a combination of medroxyprogesterone and conjugated equine estrogens) increased the risk of breast cancer, stroke, heart attack and blood clots (all FDA-approved combination hormonal products contain a synthetic Progestin and not a bio-identical Progesterone)

- 2002 Post WHI, women and healthcare providers shifted to Bio-Identical Hormone Therapy (BHRT) containing bio-identical estradiol and bio-identical progesterone as an alternative despite being unapproved drugs that are not covered by insurance
  - Over 90M+ scripts of synthetic hormone therapy prescribed annually before 2002, declining to ~26M in 2015

  - Today, patients have the choice between three therapies:
    - FDA-approved, synthetic combination hormones
    - FDA-approved, separate bio-identical hormone products
    - Unapproved, compounded bio-identical hormones that have not been proven safe and effective, or covered by insurance

- Compounding filled the need for BHRT
  - 30M scripts (3M women) of Compounded Bio-identical Hormone Therapy (CBHRT) prescribed annually in the U.S. currently

- All the major medical societies and the FDA discourage the prescribing of compounded hormones

- No FDA-approved BHRT bio-identical combination product of estradiol + progesterone

- If approved, TX-001HR would become the first and only FDA-approved bio-identical combination product to fill this unmet need

---

1) Symphony Health Solutions PHAST Data powered by IDV; Annual 2015
2) The reported number of annual custom compounded hormone therapy prescription of oral and transdermal estradiol and progesterones taken combined and in combination (26MM to 33MM)
**TX-001HR – Potential Best in Class Therapy**

**Potential first and only:**
1) Bio-identical combination estradiol & progesterone
2) FDA-approved

**Dosing and Delivery**
- Once-a-day single oral softgel capsule

**Addresses Unmet Medical Need**
- First and only combination of bio-identical estradiol and bio-identical progesterone product candidate
- Single combination dose option
- Positive Phase 3 Replenish Trial safety and efficacy results
- Potential third-party reimbursement, if approved

**PDUFA target action date October 28, 2018**
- Strong patent estate with patent expirations starting 2032

**Benefits to women, healthcare providers, and pharmacies**

---

1) NDA submitted December 28, 2017; FDA PDUFA date October 28th, 2018
2) Reimbursement anticipated if FDA-approved
### Multi-Billion Dollar Total Substitutable Market Opportunity

<table>
<thead>
<tr>
<th><strong>TX-001HR Substitutable Market (if approved)</strong></th>
<th><strong>FDA-Approved</strong></th>
<th><strong>Compounded Combination Bio-Identical E+P</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Separate Bio-Identical E &amp; P Pills</strong></td>
<td>~3.8 million&lt;sup&gt;1&lt;/sup&gt;</td>
<td>~3 million&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Combination Synthetic E+P&lt;sup&gt;1&lt;/sup&gt;</strong></td>
<td>~3 million&lt;sup&gt;2&lt;/sup&gt;</td>
<td>12 – 18 million</td>
</tr>
<tr>
<td><strong>TRx US:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TX-001HR Potential Substitutable Market</strong></td>
<td>$760M-$950M&lt;sup&gt;3&lt;/sup&gt;</td>
<td>$600M-$750M&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>TX-001HR Total Substitutable Market Opportunity</strong></td>
<td></td>
<td><strong>$3.7B – $6.1B</strong></td>
</tr>
</tbody>
</table>

#### Product Use by Age

<table>
<thead>
<tr>
<th></th>
<th>AGES 41-50</th>
<th>AGES 51-60</th>
<th>AGES 61-70</th>
<th>AGES 71+</th>
<th>TRx Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Progesterone</strong></td>
<td>903,680</td>
<td>1,596,847</td>
<td>902,733</td>
<td>399,665</td>
<td>3,802,925&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Estradiol</strong></td>
<td>2,297,141</td>
<td>5,033,146</td>
<td>2,772,199</td>
<td>1,476,272</td>
<td>11,578,758&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

- **FDA-approved separate bio-identical estrogen and progesterone channel** alone represents up to $950M annually at a WAC price of $250
  - 2 separate copays
  - Not FDA approved to be used together for endometrial protection
- **Potential billion dollar opportunity with even only limited penetration into compounding channel**

---

1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2017
2) Includes the following drugs: Activella<sup>®</sup>, FemHRT<sup>®</sup>, Angelq<sup>®</sup>, Generic 17β- Progestins, Prempro<sup>®</sup>, Premphase<sup>®</sup>, Duavee<sup>®</sup>, Brisdelle<sup>®</sup>
3) Assume WAC pricing between $200-250

All trademarks are the property of their respective owners.
TX-001HR Could Fulfill Therapeutic Gap For Stakeholders

**Patients**
- If approved, meet demand for bio-identical hormone therapy with a product approved by FDA on safety and efficacy
- Reduce of out-of-pocket costs via insurance coverage
- Convenience of one combination product
- Widely acceptable at pharmacies and not just compounding pharmacies

**Healthcare Providers**
- First and only FDA-approved bio-identical combination hormone therapy
- Clinically validated dose regimen
- Eliminate risks of compounded hormone therapy
- Meet patient demands and reduce patient out-of-pocket costs via insurance coverage
- Follow medical standards of care and society guidelines while reducing liability

**Pharmacies**
- Meet patient and physician demand for bio-identical hormone therapy
- Assuming third-party reimbursement, significantly improve net margin per script
- Lower certain legal and regulatory costs and risks

**FDA/Regulatory Bodies**
- Reduce need for and use of compounded hormone products
- Full enforcement of regulations regarding compounded hormones
BIO-IGNITE™ started as an outreach program to quantify the number of compounded bio-identical estradiol and progesterone prescriptions currently dispensed by the 3,000 high-volume compounding pharmacies, and qualify their interests in distributing our hormone product candidates, if approved.

WHAT IT HAS BECOME:
A four-phase strategic initiative to activate all current stakeholders involved in the BHRT community. Ensuring that TX-001HR has the best national access and uptake possible.

Compounding Pharmacy Partnership Strategy

- **Phase 1**: Initial Outreach
- **Phase 2**: Program Dev.
- **Phase 3**: IMVEXXY Launch
- **Phase 4**: TX-001HR National Rollout
Bio-Identical Customization

Customization of therapy at compounding pharmacies refers to addressing the overall patient condition including menopausal symptoms, adrenal function, libido, energy levels, thyroid function and nutrition, rather than through micro-dose changes in estrogen/progesterone amounts based on blood levels.

**Estradiol & Progesterone Claims**
- Base for all Patients
- Controls VMS symptoms
- Promotes sleep & calming
- Progesterone to oppose Estradiol - safety

**Estrone, Estriol & DHEA Claims**
- Breast cancer reduction/prevention
- Decrease clotting
- Glucose maintenance
- Improves lipids profile

**Testosterone Claims**
- Libido
- Muscle tone
- Improves skin turgor
- Emotional well-being

**Thyroid (T3, T4) Claims**
- Weight gain
- Lack of Energy
- Depression
- Memory

**Supplements**
- Vitamin D3
- Melatonin (sleep)
- Omega-3

**TX-001HR Doses**
- 1 mg/100 mg
- 0.5 mg/100 mg
- Covers >80% of Compounded E+P

**Continued Testing**
- Blood, Saliva, Urine
BIO-IGNITE Progress and Results
Partnerships with Large Pharmacy Network and Individual Pharmacies

**Pharmacy Network and Individual Pharmacy Partners**

- **Combination Bio-Identical E+P Scripts**
  - ~1,500,000 prescriptions annually

**# of Pharmacies**

- >300 Pharmacies In Network
- >400 Pharmacies with Prescription Data
- >500,000 prescriptions annually

---

*Formerly known as Premier Value Pharmacy Compounding Network*
# USP <800> Expenses Create Large Barriers for Compounders

<table>
<thead>
<tr>
<th>USP &lt;800&gt; Requirements</th>
<th>Cost</th>
<th>Implementation Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Segregated Clean Room:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- USP &lt;800&gt; Design</td>
<td>$60,000 - $200,000</td>
<td>1 year – 1.5 years</td>
</tr>
<tr>
<td>- Construction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventilation System</td>
<td>$25,000 - $50,000</td>
<td></td>
</tr>
<tr>
<td>New Equipment for Hazardous Compounding</td>
<td>$15,000 - $50,000</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>$100,000 - $300,000</td>
<td>1 year – 1.5 years</td>
</tr>
</tbody>
</table>

- High upfront capital expenditures required for compliance
- Long implementation time
- Increased ongoing operating expenses associated with capital expenditures

Estimates provided from Johnson’s Compounding and Bird’s Hill Pharmacy
## Economic Support TXMD Partnership for Patient Care

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Co-Pay</td>
<td>$50.00</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Third-Party Reimbursement</td>
<td>$115.00</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Net Revenue</strong></td>
<td>$165.00</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Costs of Good Sold</td>
<td>$7.50</td>
<td>$7.50</td>
<td>$7.50</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>$157.50</td>
<td>$42.50</td>
<td>$42.50</td>
</tr>
<tr>
<td>Gross margin</td>
<td>95.5%</td>
<td>85.0%</td>
<td>85.0%</td>
</tr>
<tr>
<td><strong>Operating Expenses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G&amp;A</td>
<td>$15.00</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>S&amp;M</td>
<td>$7.50</td>
<td>$7.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Additional Compounding Costs¹</td>
<td>$15.00</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td><strong>Cost of USP &lt;800&gt; Requirements²</strong></td>
<td>-</td>
<td>-</td>
<td>$10.00</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>$37.50</td>
<td>$37.50</td>
<td>$47.50</td>
</tr>
<tr>
<td><strong>Pre-Tax Profit</strong></td>
<td>$120.00</td>
<td>$5.00</td>
<td>$(5.00)</td>
</tr>
</tbody>
</table>

1) Includes additional labor, pharmacists, technicians, regulatory, and legal expenses
2) December 2019 Implementation; includes >$150,000 capital expenditure as well as new identification requirements for receipt, storage, mixing, preparing, compounding, dispensing, and administration of hazardous drugs
Annovera™
(Segesterone Acetate/Ethinyl Estradiol Vaginal System)

Approved for use by females of reproductive potential to prevent pregnancy. (Limitation of use: Not adequately evaluated in females with a body mass index of >29 kg/m²).
Annovera - 1-Year Vaginal System

First and only patient-controlled, procedure-free, long-acting, reversible birth control

- Annovera approved on August 10, 2018
  - Segesterone acetate component of Annovera classified as NCE with 5 year exclusivity
- Developed by the Population Council – developer of multi-billion dollar long acting contraceptive products
  - ParaGard® and Mirena® IUDs; Norplant® and Jadelle® implants; and Progering®
- Benefits
  - Increase compliance over short acting products
  - Offer women a long-term birth control option without requiring a procedure for insertion and removal like IUDs or implants
  - Allow women who haven’t had a child (nulliparous) or are not in a monogamous relationship - who are often counseled against IUDs due to the potential risk of infertility - access to long-term reversible birth control

The vaginal system is composed of a “squishy” silicone elastomer
- 21/7 days cyclical dosing regimen for one year (13 cycles)
- 89% overall patient satisfaction in clinical trials\(^1\)

Average daily release over one year of use:
- 0.15 mg/day segesterone acetate
- 0.013 mg/day ethinyl estradiol

Nestorone: progesterone derived unique progestin\(^2\)
- High progestational potency and anti-ovulatory activity
- No androgenic, estrogenic or glucocorticoid effects at contraceptive doses

Strong safety and efficacy data

High patient satisfaction and acceptability

Clinical Trial Experience

Efficacy & Safety

- Based on two pivotal Phase 3 clinical trials with 2,308 women
  - Efficacy and safety consistent with other birth control pills, patches and hormonal rings

Efficacy

- Highly efficacious in preventing pregnancy when used as directed (97.3%)
  - Primary Endpoint Pearl Index was 2.98 per 100 woman-years
  - Consistent with all other combination hormone birth control pills, patches and rings

Safety

- Class labeling for combination hormonal contraceptives (CHCs)
- All CHCs carry the boxed warning about cigarette smoking and serious cardiovascular events, particularly for women over age 35
- The risk profile is consistent with other CHCs
- The most common adverse reactions include headache, nausea/vomiting, vulvovaginal mycotic infections, abdominal pain, dysmenorrhea, vaginal discharge, UTIs, among others
- The most common adverse reactions leading to discontinuation were:
  - Irregular bleeding (1.7%), headache (1.3%), vaginal discharge (1.3%), and nausea/vomiting (1.2%)

1 http://annovera.com/pi.pdf
Phase 3 Acceptability Study
Demonstrated 1-Year Contraceptive Vaginal System High User Satisfaction

Acceptability Data

- Phase 3 acceptability study (n=905 subjects)
- Overall satisfaction 89% related to ease of use, side effects, expulsions/feeling the product, and physical effect during sexual activity
- High rates of adherence (94.3%) and continuation (78%)

<table>
<thead>
<tr>
<th>Ease of inserting (N=905)</th>
<th>Ease of removing (N=905)</th>
<th>Ease of remembering CVR insertion (N=905)</th>
<th>Ease of remembering CVR removal (N=905)</th>
<th>No side effects reported on questionnaire (N=905)</th>
</tr>
</thead>
<tbody>
<tr>
<td>90.8% (n=823)</td>
<td>88.2% (n=798)</td>
<td>87.6% (n=793)</td>
<td>85.2% (n=771)</td>
<td>81.8% (n=740)</td>
</tr>
</tbody>
</table>

### Annovera Key Clinical Attributes

#### Clinical Attributes
- Only FDA approved long-acting reversible birth control that doesn’t require a procedure or repeat doctor’s visit
  - Empowers women to be in control of their fertility and menstruation
  - Annovera is the only user-directed single 12-month birth control product
- Highly effective in preventing pregnancy when used as directed (97.3%)
- High patient satisfaction in clinical trials\(^1\) (89% overall satisfaction)
- Low daily release of ethinyl estradiol (13 mcg)
- Only product with new novel progestin - segesterone acetate\(^2\)
  - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses
- Favorable side effect profile including low rates of discontinuation related to irregular bleeding (1.7%)
- Safety profile generally consistent with other CHC products, including boxed warning

#### Physical Attributes
- Softer and more pliable than NuvaRing
- Acceptable for women who haven’t had a child (nulliparous) or are not in a monogamous relationship\(^3\)
- “Vaginal System” – the only product in a new class of contraception with potential for $0 co-pay
- Cost and convenience (pharmacy and doc visits)
- Does not require refrigeration by HCP

---

3 Lohr, et al. Use of intrauterine devices in nulliparous women. Contraception 95 (2017); 529-537
U.S. Prescription Contraceptive Market

- One of the largest therapeutic categories by script count
- ~ > $5B U.S. net sales

**Daily Oral Contraceptives**

- OC’s continue to lose market share to longer acting solutions such as IUDs, Implants and Rings

**Long Acting Reversible Contraceptives**

- IUDs and Implants are experiencing significant growth as the market shifts towards long-acting solutions

---

Top Contraceptive Products Based on Revenue

2017 Net Revenue (mm)

MUVARING $564

NEXPLANON IMPLANT $496

LO LOESTRIN FE BIRTH CONTROL PILL $420

MIRENA IUD FAMILY (INCLUDES MIRENA, KYLEENA & SKYLA)

This includes 3 products $841

$0 $100 $200 $300 $400 $500 $600 $700 $800 $900

Company filings; Symphony Health Solutions PHAST Data powered by IDV. Net sales as reported in company filings.
Large Established Ring Market

**Annovera compared to existing NuvaRing and potential NuvaRing generic**

- 1-year duration (vs. monthly)
- Soft, pliable, squishy (vs. semi-rigid ring body)
- 89% overall patient satisfaction in clinical trials\(^1\)
- High rates of adherence (94.3%) and continuation (78%)\(^1\)
- New/Lower hormones
  - New progestin segesterone acetate (vs. etonogestrel)
    - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses\(^2\)
    - 13 mcg ethinyl estradiol (vs. 15 mcg)
- No monthly hormonal burst from each new NuvaRing placed
- No refrigeration required by HCP
- Low discontinuation rates\(^3\)
  - Annovera: Irregular bleeding 1.7%, headache/migraine 1.3%, vaginal discharge/infections 1.3%, nausea/vomiting 1.2%
  - NuvaRing: Device-related events 2.7%, mood changes 1.7%, headache (including migraine) 1.5% and vaginal symptoms 1.2%
- Less expensive ~$1,400 for Annovera vs. $2,013 for NuvaRing based on annual WAC price
- “Vaginal System” - a new class of contraception with potential for $0 co-pay
- NuvaRing no longer actively promoted

---


\(^3\) Based on product Prescribing Information; not a head to head comparison
Unique Product Characteristics Should Lead to Good Payer Coverage

- Anticipate parity or discount pricing level ~$1,400 annual WAC cost
  - 30% decrease to annual WAC of NuvaRing, reflects TXMD’s responsible brand pricing
  - Allows for improved patient adherence and a potential decrease in unplanned pregnancies
  - Only one pharmacy fill fee per year (estimated savings of $33 annually per patient)
  - No repeat office visit or procedure fees (several hundred dollars per patient)
  - Contains ethinyl estradiol and Nestorone®, a new and unique progestin
  - “Vaginal System”- a new class of contraception with potential for $0 co-pay

The Affordable Care Act (ACA) mandates that private health plans provide coverage for one treatment per class of contraception used by women with no patient out-of-pocket costs
# 1-Year Vaginal Contraceptive System Serves an Unmet Need in the U.S. Contraceptive Market

<table>
<thead>
<tr>
<th></th>
<th>Annovera™</th>
<th>NuvaRing®</th>
<th>IUD’s</th>
<th>Oral Contraceptives</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration of Action</strong></td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>1 year (21/7 regimen)</td>
<td>1 month (21/7 regimen)</td>
<td>3-10 years</td>
<td>Daily pill intake</td>
</tr>
<tr>
<td><strong>Patient Control</strong></td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
</tr>
<tr>
<td></td>
<td>Removable at any time</td>
<td>Removable at any time</td>
<td>Procedure required</td>
<td>Stop at any time</td>
</tr>
<tr>
<td><strong>Nulliparous Women</strong></td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Yes</td>
<td>Not universally acceptable</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Product Administration</strong></td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>Patient administered pliable ring</td>
<td>Patient administered Semi-rigid ring</td>
<td>Physician in-office procedure</td>
<td>Oral intake</td>
</tr>
<tr>
<td><strong>Patient Convenience</strong></td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>1 doctor’s visit, 1 pharmacy visit per year</td>
<td>Monthly pharmacy visit</td>
<td>Physician in-office procedure HCP stocking required</td>
<td>Daily pill presents compliance/adherence risks; potential increase in unplanned pregnancies</td>
</tr>
<tr>
<td><strong>Healthcare Provider Convenience</strong></td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>Filled at pharmacy; No refrigeration; No inventory or capital outlay</td>
<td>Filled at pharmacy; Refrigeration required prior to being dispensed</td>
<td>HCP required to hold inventory</td>
<td>Filled at pharmacy</td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>✗</td>
</tr>
<tr>
<td></td>
<td>$1,400 WAC</td>
<td>$154.89/28 days, or 1 year cost of $2013.57 (13 rings/year)</td>
<td>$909 WAC + insertion and removal costs (good for 5 years)</td>
<td>Lo Loestrin® Fe $128.51/28 days, or 1 year cost of $1,670.63 (13/year)</td>
</tr>
<tr>
<td><strong>Contraceptive Class</strong></td>
<td>✔️ Vaginal System</td>
<td>✔️ Vaginal Ring</td>
<td>✗ IUD</td>
<td>✗ Oral</td>
</tr>
</tbody>
</table>

- ✔️ 89% overall patient satisfaction in clinical trials, 94% adherence rate, 78% continuation rate
- ✗ “Vaginal System” potential for a new class of contraception with $0 co-pay
- ✔️ Segesterone acetate component of Annovera classified as NCE with 5 year exclusivity

Chart comparisons for product characteristics only and are not intended to imply safety or efficacy comparisons.
Commercialization Strategy

Launch Timing
- Estimated to be commercially available as early as Q3’19 with commercial launch as early as Q4’19 to Q1’20

Attractive Market Segments for Annovera
- NuvaRing users – leveraging the physical and clinical strengths of Annovera
  - No additional sales representatives needed
  - 81% of total prescribers within current 150 TXMD territories¹
- Women who want long-acting reversible contraception but don’t want a procedure
- Providers who do not want to purchase and manage inventory of IUDs and implants
- Women who haven’t had a child (nulliparous) or are not in a monogamous relationship and want long-term contraceptive options

¹ IQUVIA Data
Complete Women’s Healthcare Portfolio

Annovera™
Vasomotor symptoms affect up to 75% of perimenopausal women

TX-001HR*
(D Estradiol Vaginal Inserts)

DYSPAREUNIA
(Vulvar & Vaginal Atrophy)

PRENATAL CARE
~60,000 New Prenatal Patients
Many will go on contraception after breastfeeding

CONTRACEPTION/ FAMILY PLANNING - PERIMENOPAUSE

VASOMOTOR SYMPTOMS

Vasomotor symptoms affect up to 75% of perimenopausal women

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

*Investigational product, pending FDA approval

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553986/
Contraceptive Pipeline

<table>
<thead>
<tr>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Year Contraceptive Vaginal System (NES/EE)</td>
<td></td>
<td></td>
<td></td>
<td>Approved 08/10/2018</td>
</tr>
<tr>
<td>3-Month Contraceptive Vaginal Ring (NES/E2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Next Generation
1-Year Contraceptive Vaginal System (NES/EE)

Exclusive rights to negotiate co-development and marketing rights:
- 3 month ring using NES plus bio-identical Estradiol (E2) (Phase 2)
- 1 year contraceptive vaginal system (NES/EE) life cycle management

1 TXMD has the option to co-develop and market in the US, if approved.
Committed to Become the Leading Women’s Health Company
TherapeuticsMD, A Premier Women’s Health Company

Annovera™

vitaMedMD®

Annovera™

TX-Q01HR*

Imvexxy™

CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/
FAMILY PLANNING - PERIMENOPAUSE

VASOMOTOR
SYMPTOMS

DYSPAREUNIA
(Vulvar & Vaginal Atrophy)

CONTRACEPTION

PRENATAL CARE

CONTRACEPTION/
FAMILY PLANNING - PERIMENOPAUSE

VASOMOTOR
SYMPTOMS

DYSPAREUNIA
(Vulvar & Vaginal Atrophy)

REPRODUCTIVE HEALTH

MENOPAUSE MANAGEMENT

*Investigational product, pending FDA approval
Significant Insider and Institutional Share Ownership

- Board of Directors and Executive Officers have long-term commitment to the company
  - Beneficially own approximately 20% of the company’s shares
  - Three founding executives beneficially own approximately 17% of the company’s shares
    - Includes vested options to acquire approximately 4 million shares of common stock (approximately 9% of such executives’ current beneficial ownership) that were originally issued on January 1, 2009 and expire on January 1, 2019

- Large institutional holder support
  - Large institutional holders – many long-term – beneficially own more than 55% of the company’s outstanding shares
TXMD: Financial Snapshot

- **Listing Exchange**: TXMD Nasdaq Listed
- **Insider Ownership**: ~20% (October 2018)
- **Shares Outstanding**: 235.4M (Post-offerings Aug 6, 2018)
- **Debt**: $75M (as of June 30, 2018)
- **Cash**: $154.4M (as of June 30, 2018)
- **Net Cash Raised in Aug Offerings**: $90M
Thank You